Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 113 clinical trials
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). …

HER2
endocrine therapy
metastatic cervical cancer
targeted therapy
fulvestrant
  • 27 views
  • 03 Jul, 2022
  • 60 locations
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (innovaTV 207)

This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are four parts to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). In …

bevacizumab
cancer
carboplatin
gemcitabine
kinase inhibitor
  • 247 views
  • 30 Jun, 2022
  • 32 locations
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations

  • 5 views
  • 20 Jun, 2022
  • 55 locations
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

HER2
targeted therapy
chemotherapy regimen
epidermal growth factor receptor
melanoma skin
  • 13 views
  • 14 Jun, 2022
  • 64 locations
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (SQ-NSCLC). Subjects may participate in the pre-screening phase at initial diagnosis or following prior lines of therapy

HRAS
platelet count
lung carcinoma
metastasis
systemic therapy
  • 19 views
  • 12 Feb, 2022
  • 27 locations
  • 3 views
  • 14 Mar, 2022
  • 1 location
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

patients with stage IV non-squamous non-small cell lung cancer (NSCLC) without progressive disease (PD), as confirmed on CT scans, after induction therapy with carboplatin/pemetrexed/pembrolizumab (CPP

cancer
carboplatin
growth factor
progressive disease
measurable disease
  • 8 views
  • 04 Feb, 2022
  • 3 locations
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

This study is a single-arm, prospective, multi-center clinical trial. designed to evaluate patients with stage IV inability to receive or refuse chemotherapy.Efficacy and safety of first-line treatment with Camrelizumab and Endo in advanced lung squamous cell carcinoma

neutrophil count
squamous cell carcinoma
adjuvant chemotherapy
chemoradiotherapy
lung carcinoma
  • 0 views
  • 01 Mar, 2022
  • 1 location
Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

To determine the efficacy of combined afatinib and prednisone in previously treated advanced squamous NSCLC

  • 0 views
  • 07 Apr, 2022
  • 1 location
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small

  • 0 views
  • 07 May, 2021
  • 1 location